N P Bowles1, S S Thosar2, M X Herzig2, S A Shea2. 1. Oregon Institute of Occupational Health Sciences, Oregon Health and Sciences University, 3181 S.W. Sam Jackson Park Rd. L606, Portland, OR, 97239, USA. bowlesn@ohsu.edu. 2. Oregon Institute of Occupational Health Sciences, Oregon Health and Sciences University, 3181 S.W. Sam Jackson Park Rd. L606, Portland, OR, 97239, USA.
Abstract
PURPOSE OF REVIEW: Given the emerging knowledge that circadian rhythmicity exists in every cell and all organ systems, there is increasing interest in the possible benefits of chronotherapy for many diseases. There is a well-documented 24-h pattern of blood pressure with a morning surge that may contribute to the observed morning increase in adverse cardiovascular events. Historically, antihypertensive therapy involves morning doses, usually aimed at reducing daytime blood pressure surges, but an absence of nocturnal dipping blood pressure is also associated with increased cardiovascular risk. RECENT FINDINGS: To more effectively reduce nocturnal blood pressure and still counteract the morning surge in blood pressure, a number of studies have examined moving one or more antihypertensives from morning to bedtime dosing. More recently, such studies of chronotherapy have studied comorbid populations including obstructive sleep apnea, chronic kidney disease, or diabetes. Here, we summarize major findings from recent research in this area (2013-2017). In general, nighttime administration of antihypertensives improved overall 24-h blood pressure profiles regardless of disease comorbidity. However, inconsistencies between studies suggest a need for more prospective randomized controlled trials with sufficient statistical power. In addition, experimental studies to ascertain mechanisms by which chronotherapy is beneficial could aid drug design and guidelines for timed administration.
PURPOSE OF REVIEW: Given the emerging knowledge that circadian rhythmicity exists in every cell and all organ systems, there is increasing interest in the possible benefits of chronotherapy for many diseases. There is a well-documented 24-h pattern of blood pressure with a morning surge that may contribute to the observed morning increase in adverse cardiovascular events. Historically, antihypertensive therapy involves morning doses, usually aimed at reducing daytime blood pressure surges, but an absence of nocturnal dipping blood pressure is also associated with increased cardiovascular risk. RECENT FINDINGS: To more effectively reduce nocturnal blood pressure and still counteract the morning surge in blood pressure, a number of studies have examined moving one or more antihypertensives from morning to bedtime dosing. More recently, such studies of chronotherapy have studied comorbid populations including obstructive sleep apnea, chronic kidney disease, or diabetes. Here, we summarize major findings from recent research in this area (2013-2017). In general, nighttime administration of antihypertensives improved overall 24-h blood pressure profiles regardless of disease comorbidity. However, inconsistencies between studies suggest a need for more prospective randomized controlled trials with sufficient statistical power. In addition, experimental studies to ascertain mechanisms by which chronotherapy is beneficial could aid drug design and guidelines for timed administration.
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2014-01-21 Impact factor: 29.690
Authors: Yasmina Serinel; Brendon J Yee; Ronald R Grunstein; Keith H Wong; Peter A Cistulli; Hisatomi Arima; Craig L Phillips Journal: Thorax Date: 2016-12-14 Impact factor: 9.139
Authors: Diana E Ayala; Ana Moyá; Juan J Crespo; Carmen Castiñeira; Manuel Domínguez-Sardiña; Sonia Gomara; Elvira Sineiro; Artemio Mojón; María J Fontao; Ramón C Hermida Journal: Chronobiol Int Date: 2012-10-25 Impact factor: 2.877
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Benjamin Smarr; Tamara Cutler; Dawn H Loh; Takashi Kudo; Dika Kuljis; Lance Kriegsfeld; Cristina A Ghiani; Christopher S Colwell Journal: J Neurosci Res Date: 2019-07-29 Impact factor: 4.164
Authors: Yuichiro Yano; Rikki M Tanner; Swati Sakhuja; Byron C Jaeger; John N Booth; Marwah Abdalla; Daniel Pugliese; Samantha R Seals; Gbenga Ogedegbe; Daniel W Jones; Paul Muntner; Daichi Shimbo Journal: JAMA Cardiol Date: 2019-09-01 Impact factor: 14.676
Authors: Ramón C Hermida; Michael H Smolensky; Horia Balan; Richard J Castriotta; Juan J Crespo; Yaron Dagan; Sherine El-Toukhy; José R Fernández; Garret A FitzGerald; Akio Fujimura; Yong-Jian Geng; Ramón G Hermida-Ayala; Antonio P Machado; Luiz Menna-Barreto; Artemio Mojón; Alfonso Otero; R Daniel Rudic; Eva Schernhammer; Carsten Skarke; Tomoko Y Steen; Martin E Young; Xiaoyun Zhao Journal: Chronobiol Int Date: 2020-12-20 Impact factor: 3.749